SAT-LB15 24-Month Efficacy and Safety of Once Weekly and Every Other Week Administration of GX-H9, Hybrid FC-Fused Long-Acting Human Growth Hormone: A Phase 2 Study in Children With Growth Hormone Deficiency

Objectives GX-H9 is a long-acting form of recombinant human GH under clinical development for both adults and children with GHD. In this report, 24-month efficacy and safety of once weekly and every other week (EOW) administration of GX-H9 were evaluated, in addition to Genotropin(®) switch-ability...

Descripción completa

Detalles Bibliográficos
Autores principales: Malievskiy, Oleg, Mykola, Aryaev, Zelinska, Nataliya, Bolshova, Elena, Senatorova, Ganna, Oroszlán, György, Skorodok, Julia, Peterkova, Valentina, Chorna, Nataliya, Sorokman, Tamila, Yang, Seung, Lee, Ji-Eun, Muzsnai, Agota, Hwang, Jin Soon, Lee, Sang-Yoon, Son, HyunJoo, Heo, SuJin, Heo, Minkyu, Choi, Yun Jung, Sung, Young Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208270/
http://dx.doi.org/10.1210/jendso/bvaa046.2162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208270/
http://dx.doi.org/10.1210/jendso/bvaa046.2162

Ejemplares similares